SpringWorks Therapeutics Valuation

SpringWorks Therapeutics Investor Information

About 87.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.41. SpringWorks Therapeutics had not issued any dividends in recent years. Based on the key indicators related to SpringWorks Therapeutics' liquidity, profitability, solvency, and operating efficiency, SpringWorks Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in August.

SpringWorks Therapeutics Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. SpringWorks Therapeutics has an asset utilization ratio of 32.62 percent. This suggests that the Company is making $0.33 for each dollar of assets. An increasing asset utilization means that SpringWorks Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.

SpringWorks Therapeutics Ownership Allocation

SpringWorks Therapeutics shows a total of 75.35 Million outstanding shares. The majority of SpringWorks Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in SpringWorks Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in SpringWorks Therapeutics. Please pay attention to any change in the institutional holdings of SpringWorks Therapeutics as this could imply that something significant has changed or is about to change at the company. On July 11, 2025, Representative Gilbert Cisneros of US Congress acquired $15k to $50k worth of SpringWorks Therapeutics's common stock.

SpringWorks Therapeutics Profitability Analysis

The company reported the previous year's revenue of 191.59 M. Net Loss for the year was (258.13 M) with profit before overhead, payroll, taxes, and interest of 204.8 M.

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

If you are still planning to invest in SpringWorks Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SpringWorks Therapeutics' history and understand the potential risks before investing.